New Report: Top pharma companies fail to address industry best practices on HIV/AIDS

The Interfaith Center on Corporate Responsibility released a comprehensive scorecard evaluating the pharmaceutical industry's efforts in the fight against HIV/AIDS...The ICCR report highlights the large disparities between industry best practices in addressing...HIV/AIDS...and the current actions of 15 leading pharmaceutical companies. "We see two major problems - a failure to develop new medicines that address neglected diseases and a lack of access for poor patients to the existing medicines," said Daniel Rosan, ICCR's Program Director for Public Health and author of the report... [companies rated: Abbott Laboratories, AstraZeneca, Boehringer-Ingelheim, Bristol-Myers Squibb, GlaxoSmithKline, Gilead Sciences, Johnson & Johnson, Eli Lilly, Merck, Novartis, Pfizer, Hoffmann-La Roche (part of Roche), sanofi-aventis, Schering-Plough, Wyeth]

Línea del tiempo

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

Fecha:

4 Mar 2014

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
[PDF] Benchmarking AIDS: 2006 Year End Update

Fecha:

30 Nov 2006

Tipo de contenido:

Artículo

Idiomas disponibles: English
Response by Merck: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Merck - finds none has comprehensive approach.

Fecha:

13 Sep 2006

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Response by Wyeth (part of Pfizer): Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Wyeth - finds none has comprehensive approach.

Fecha:

13 Sep 2006

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Response by Bristol-Myers Squibb: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Bristol-Myers Squibb - finds none has comprehensive approach.

Fecha:

13 Sep 2006

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Company responses to Interfaith Center on Corporate Responsibility report "Benchmarking AIDS"

Fecha:

12 Sep 2006

Tipo de contenido:

Artículo

Idiomas disponibles: English
Response by Boehringer Ingelheim: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Boehringer-Ingelheim - finds none has comprehensive approach.

Fecha:

6 Sep 2006

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Response by AstraZeneca: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including AstraZeneca - finds none has comprehensive approach.

Fecha:

6 Sep 2006

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Reclaman mayor compromiso de las farmacéuticas

Fecha:

31 Ago 2006

Tipo de contenido:

Artículo
Eli Lilly did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Eli Lilly - finds none has comprehensive approach.

Fecha:

23 Ago 2006

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Response by Pfizer: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Pfizer - finds none has comprehensive approach.

Fecha:

23 Ago 2006

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Response by Novartis: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Novartis - finds none has comprehensive approach.

Fecha:

23 Ago 2006

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
International AIDS Conference: "Treatment Access, TRIPS and Trip-ups"

Fecha:

17 Ago 2006

Tipo de contenido:

Artículo

Idiomas disponibles: English
[PPT] presentation: "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"

Fecha:

17 Ago 2006

Tipo de contenido:

Artículo

Idiomas disponibles: English
New Report: Top pharma companies fail to address industry best practices on HIV/AIDS

Fecha:

14 Ago 2006

Tipo de contenido:

Artículo

Idiomas disponibles: English
Sanofi-Aventis did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including sanofi-aventis - finds none has comprehensive approach.

Fecha:

1 Ago 2006

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

Fecha:

1 Ago 2006

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Hoffmann-La Roche (part of Roche) did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Hoffman-La Roche - finds none has comprehensive approach.

Fecha:

8 Ene 2006

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English
Gilead Sciences did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Gilead - finds none has comprehensive approach.

Fecha:

8 Ene 2006

Tipo de contenido:

Respuesta de la empresa

Idiomas disponibles: English

Ver la historia completa

Cargar más Ver menos

Business & Human Rights
Resource Centre

El Tratado entre México, Estados Unidos y Canadá (T-MEC) y el panorama laboral en la industria de la indumentaria

Comunidad sobre Debida Diligencia en Derechos Humanos en la Agroindustria

Actualización Semanal 19 de diciembre de 2024

Actualizaciones Trimestrales de Responsabilidad Legal Empresarial – Número 51, diciembre de 2024: Negociaciones del tratado vinculante 2024: Panorama general, cuestiones clave y oportunidades

Centro de Información sobre Empresas y Derechos Humanos

El Tratado entre México, Estados Unidos y Canadá (T-MEC) y el panorama laboral en la industria de la indumentaria

Comunidad sobre Debida Diligencia en Derechos Humanos en la Agroindustria

Actualización Semanal 19 de diciembre de 2024

Actualizaciones Trimestrales de Responsabilidad Legal Empresarial – Número 51, diciembre de 2024: Negociaciones del tratado vinculante 2024: Panorama general, cuestiones clave y oportunidades

Esta página no está disponible en Español y está siendo mostrada en English

New Report: Top pharma companies fail to address industry best practices on HIV/AIDS

Línea del tiempo

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

[PDF] Benchmarking AIDS: 2006 Year End Update

Response by Merck: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Merck - finds none has comprehensive approach.

Response by Wyeth (part of Pfizer): Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Wyeth - finds none has comprehensive approach.

Response by Bristol-Myers Squibb: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Bristol-Myers Squibb - finds none has comprehensive approach.

Company responses to Interfaith Center on Corporate Responsibility report "Benchmarking AIDS"

Response by Boehringer Ingelheim: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Boehringer-Ingelheim - finds none has comprehensive approach.

Response by AstraZeneca: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including AstraZeneca - finds none has comprehensive approach.

Reclaman mayor compromiso de las farmacéuticas

Eli Lilly did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Eli Lilly - finds none has comprehensive approach.

Response by Pfizer: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Pfizer - finds none has comprehensive approach.

Response by Novartis: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Novartis - finds none has comprehensive approach.

International AIDS Conference: "Treatment Access, TRIPS and Trip-ups"

[PPT] presentation: "Benchmarking AIDS: Evaluating pharmaceutical company responses to the public health crisis in emerging markets"

New Report: Top pharma companies fail to address industry best practices on HIV/AIDS

Sanofi-Aventis did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including sanofi-aventis - finds none has comprehensive approach.

Schering-Plough did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Schering-Plough - finds none has comprehensive approach.

Hoffmann-La Roche (part of Roche) did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Hoffman-La Roche - finds none has comprehensive approach.

Gilead Sciences did not respond to: Interfaith Center on Corporate Responsibility rates 15 pharmaceutical firms on HIV/AIDS, including Gilead - finds none has comprehensive approach.